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Stem cell transplantation has been widely acknowledged for their immense potential in regenerative medi-
cine. In these procedures, the implanted cells need to maintain both their viability and functional properties 
for effective therapeutic outcomes. This has long been a subject of major concern and intensive studies. 
Microencapsulation of stem cells within polymeric microcapsules can be an efficient approach to achieve this 
goal, particularly for heart diseases. This study reports the use of biocompatible, fluorogenic genipin-cross-
linked alginate chitosan (GCAC) microcapsules in delivery of human adipose stem cells (hASCs) with an aim 
to increase the implant retention in the infarcted myocardium for maximum clinical benefits. In vitro results 
show, under hypoxic conditions, the microencapsulated cells overexpressed significantly higher amount 
of biologically active vascular endothelial growth factor (VEGF). We investigated on the in vivo potential 
using immunocompetent female rats after induction of myocardial infarction. For this, animal groups (n = 8) 
received empty control microcapsules, 1.5 ́  106 free male hASCs, or 1.5 ́  106 microencapsulated male hASCs. 
Results show significant retention (3.5 times higher) of microencapsulated hASCs compared to free hASCs 
after 10 weeks of transplantation. Microencapsulated hASCs showed significantly attenuated infarct size 
compared to free hASCs and empty microcapsule group (21.6% ± 1.1% vs. 27.2% ± 3.1% vs. 33.3% ± 3.2%; 
p < 0.05), enhanced vasculogenesis, and improved cardiac function (fractional shortening: 24.2% ± 2.1% vs. 
19.1% ± 0.5% vs. 12.0% ± 4.0%; p < 0.05). These data suggest that microencapsulated hASCs can contribute 
significantly to the improvement in cardiac functions. Their greater retentions exhibit reduced fibrosis and 
cardiac dysfunction in experimental animals. However, further research is needed to fully comprehend the 
underlying biological and immunological effects of microencapsulated hASCs, which jointly play important 
roles in cardiac repair.
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such diseases. Although the majority of cardiovascular 
research in stem cell therapy has involved bone marrow-
 derived mesenchymal stem cells (BMSCs), human adi-
pose stem cells (hASCs) are an ideal alternative and 
as a result have been researched extensively as of late 
(35,36,45). Adipose tissue, like bone marrow, is derived 
from the mesenchyme. Therefore, ASCs also have the 
potential to differentiate into mesodermal lineages. ASCs 
provide the same multipotency as BMSCs and even yield 
a higher cell number from the same amount of starting 
INTRODUCTION
Cardiovascular diseases, such as cardiomyopathy and 
ischemic heart diseases, are a major cause of concern 
all over the world (11). Ischemic heart disease refers to 
the decrease in oxygenated blood flow to the myocar-
dium or heart muscle, which leads to an inadequate sup-
ply of oxygen to the cardiac muscle eventually leading 
to a permanent damage to the cardiomyocytes followed 
by myocardial infarction (20). Stem cell transplantation 
has been considered as a major breakthrough in treating 
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material (37). The safe expendability of this tissue allows 
for large quantities of stem cells to be harvested with-
out difficulty and at minimal risk (9). Owing to their 
potency and relative abundance, ASCs may be the most 
promising and ideal stem cell studied to date (10,21,27). 
Moreover, ASCs also have natural ability to secrete vas-
cular endothelial growth factors and induce angiogenesis, 
where the newly formed vessels help in recovery of the 
blood flow in the damaged tissues, eventually leading to 
increased oxygen availability (36).
Survival of cells after intramyocardial injection is 
crucial to the efficacy of therapeutic cell transplanta-
tion. Recent studies suggest that a massive mechanical 
loss of cells takes place in the first minutes after direct 
intramyocardial injection (23,33,40). Similar problems 
were also noticed by another group where both ASCs 
and MSCs could not survive in the harsh cardiac envi-
ronment, resulting in acute transplanted cell death and 
subsequent loss of cardiac function (41). In light of the 
early time frame in which this cell loss takes place, 
it is unlikely that it happens only because of instant 
cell death of the transplanted cells. As the heart differs 
from other organs in that it is constantly contracting, it 
is possible that this may contribute to the mechanical 
loss by squeezing the injected cells out of the myocar-
dium. As a result, the cells retained in the myocardium 
immediately after injection represent only a fraction 
of those initially implanted. It is from this subset that 
biological loss can then affect the remaining number of 
surviving cells.
Extensive research has been dedicated towards the 
development of efficient cell delivery systems that could 
promote tissue regeneration. Several cell immobiliza-
tion techniques have been studied such as 3D scaffolds 
and gel-based entrapment carriers, but none has actually 
gained acceptance into the market (1,24,47,49). With 
these drawbacks and requirements in mind, studies led 
to the development of better techniques of cell deliv-
ery involving cell encapsulation within semipermeable 
microcapsules (7,8,15,30,51). This technique provides 
the advantage of localized cell retention, which in turn 
facilitates the release of therapeutic agents for prolonged 
time periods at the target site, increasing potential impact 
in tissue regeneration applications. As shown in our 
 previous studies, the use of polymeric microcapsules 
can provide an efficient delivery system for the trans-
plantation of mesenchymal stem cells and help in cell-
based gene therapy for overexpression of the therapeutic 
 proteins (29).
Current study focuses on increasing the retention of the 
transplanted cells at target site with minimum mechani-
cal and biological loss. Reducing the myocardial loss 
of cells will increase the retention of higher number of 
viable cells at the target site, which can eventually reduce 
the cardiac dysfunction. Here, we hypothesized that cell 
delivery using biodegradable polymeric microcapsules 
will be a potential tool to achieve this goal (Fig. 1). This 
is because when the size of the injectate is larger than 
the blood vessel diameter, like that of microcapsules, the 
contractive forces of the heart will be unable to wash out 
the latter into the blood stream. On the contrary, with free 
cell delivery system, the pressure generated by the injec-
tion coupled with that generated by the beating heart eas-
ily forces the grafted cells through the disrupted blood 
vessels into the systemic circulation. Moreover, the cap-
sular membrane will also protect the cells against the 
external harsh microenvironment and foreign bodies in 
the myocardium.
We have recently demonstrated, using fluores-
cent microspheres (diameter: 10 µm, impersonating 
the cells) encapsulated in standard 200 µm alginate 
poly-l-lysine microcapsules, that microcapsules can 
reduce the initial mechanical loss of microspheres in 
the beating heart as detected after 20 min of myocar-
dial transplantation in the left ventricle of infarcted rat 
heart model (2,28). We have also reported the use of 
genipin, a highly biocompatible and naturally derived 
iridoid glucoside from Gardenia fruits, for covalent 
cross-linking outermost coating of the microcapsule 
membrane for live cell encapsulation and character-
ized the microcapsule structure and key physical char-
acteristics including mechanical properties, resistance, 
permeability, and durability (7,8). In this article for the 
first time, we explore the potential of these new genipin- 
cross-linked alginate chitosan (GCAC) microcapsules 
in vivo for myocardial xenotransplantation in infarcted 
rat heart using hASCs and assess their ability to improve 
the cardiac function and diminish scar formation.
MATERIALS AND METHODS
Chemicals
Low-viscosity alginic acid sodium salt from brown 
algae (viscosity: ~250 cP, 2% in water at 25°C) and poly-
l-lysine hydrobromide (PLL; molecular weight: 27,400) 
were bought from Sigma Chemicals (St. Louis, MO). 
Chitosan (low viscosity, Mv = 7.2 ́  104 by viscometry, 
degree of deacetylation at 73.5% by titration) and genipin 
were purchased from Wako BioProducts, USA.
Cell Culture
Human ASCs (n = 1 male donor) were obtained 
from Invitrogen and cultured in Dulbecco’s modified 
Eagle’s medium (DMEM; Invitrogen) supplemented 
with 10% fetal bovine albumin (FBS). The cells were 
routinely maintained as stationary cultures in 75-cm2 
tissue culture flasks and incubated at 37°C in a con-
trolled environment with an air atmosphere of 5% CO
2
. 
Human umbilical vein endothelial cells (HUVECs) 
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Figure 1. Schematic representation of direct intramyocardial delivery of microencapsulated adipose stem cells (hASCs) at the 
 peri-infarct sites in comparison to free hASCs. We hypothesized that compared to nonencapsulated free hASCs (Method 1), the micro-
encapsulated hASCs (Method 2) can better retain the transplanted cells at the infarct site, reduce massive mechanical cell washouts 
into microcirculation, and inhibit biological cell losses induced by the beating heart. The higher retention of transplanted viable 
cells at the infarct site (in this study, 10 weeks post transplantation) can eventually facilitate superior functional improvement of the 
infarcted heart.
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(Sciencell, Carlsbad, CA, USA) were cultured and 
expanded on tissue culture flasks according to the sup-
plier’s instructions. They were cultured in endothelial 
cell medium (ECM) (Sciencell) supplemented with 5% 
FBS and placed in an incubator containing 5% CO
2 
at 37°C.
Preparation of GCAC Microcapsules Containing hASCs
Calcium-alginate beads containing ASCs were gener-
ated using an encapsulator (Inotech Corp) with a 300-µm 
nozzle, which dispenses droplets of 1.5% sodium alginate 
solution containing cells (1 ́  106 cells/ml) into a con -
stant ly stirring solution of 0.1 M CaCl
2
. After 20 min of 
stirring, the newly generated beads were coated with a 
chitosan layer by immersing them in a chitosan solution 
(2%) for 30 min. Subsequently, the beads were washed 
twice in 0.9% saline solution and immersed in genipin 
solution (5 mg/ml) for 12 h at 37°C to promote cross- 
linking with the chitosan layer. This was followed by rapid 
chelation of the inner alginate core of the microcapsules 
by incubating them in 0.055 mol/L sodium citrate 
solution for 5 min, followed by two washes in saline solution. 
To confirm the genipin cross-linking to the chitosan layer, 
the microcapsules were placed in a chambered coverglass 
system (Lab-Tek) under Laser Scanning Confocal Imaging 
System (LSM 510, Carl Zeiss, Jena, Germany) equipped 
with a Zeiss Axiovert 100M microscope. A 488-nm argon 
laser was used in the single green fluorescence mode, and 
the fluorescence was detected with the emission filter block 
BP500-550IR. Genipin reacts with amino terminals of the 
chitosan layer to emit green fluorescence on the outer 
surface of the capsule (8). After reaction confirmation, 
resulting microcapsules were thoroughly washed, replen-
ished with fresh media to promote cell growth, and placed 
in a 37°C incubator containing 5% CO
2
.
Scanning Electron Microscope: Internal Morphology  
of the hASC Containing Microcapsule
The internal morphology of the microencapsulated 
cells was studied by scanning electron microscopy (SEM) 
using a Hitachi S-4700 FE scanning microscope. The 
samples for SEM were prepared by rinsing the capsules 
with water, followed by freeze-drying and fracturing by a 
razor blade. The obtained fragmented halves of the micro-
capsules were mounted on a SEM stud with double-sided 
tape and sputter-coated with gold–palladium for 40 s.
Detection of Viable Encapsulated Cells Using Stably 
Transduced LacZ Containing hASCs
In order to assess the viability of the encapsulated cells 
hASCs were transduced with retroviral vector containing 
the LacZ gene before encapsulation. X-gal staining was 
used from time to time to indicate the viability of the 
LacZ-infected cells inside the GCAC microcapsules for 
1 month.
Assessment of Viability of Encapsulated Cells Using 
Dual Cell Staining
Viability of the ASCs within the GCAC microcapsules 
was assessed using the polyanionic acetomethoxy deri-
vate of calcein (calcein AM) and ethidium homopolymer 
EthD-III dyes (Biotium, Inc., Hayward, CA, USA) (29). 
The live cells were detected by the intracellular esterase 
mediated conversion of nonfluorescent cell-permeant 
calcein AM to fluorescent green calcein. The dead cells 
were detected by the bright red fluorescence emitted by 
EthD-III dye, which enters dead cells only through their 
damaged membranes and binds to nucleic acids. For this, 
the microcapsules were washed twice with PBS for 10 min 
each and resuspended in fresh PBS. Calcein AM (2 µM) 
and EthD-III (4 µM) were then added to the microcap-
sules and the microcapsules were incubated for 1 h before 
being examined under the fluorescent microscope.
Induction of Hypoxic and Normoxic Conditions  
and Quantification of Released VEGF From 
Encapsulated hASCs
hASCs were encapsulated in microcapsules, as des-
cribed above, and grown for 24 h so as to allow them to 
stabilize in the new environment. Similarly, equal num-
ber of free cells was cultured in a stationary flask. On the 
following day, the media from the cultures were replaced 
with fresh media containing 10% FBS and the flasks 
were placed in either normoxic (21% O
2
) or hypoxic 
(1% O
2
) conditions for 24, 48, or 96 h. To induce hypoxic 
condition, a modular incubator chamber from Billup-
Rothenberg, Inc., was used as mentioned elsewhere (32). 
At the end of the incubation period, the conditioned media 
from culture flasks were collected. Conditioned media 
from the culture flasks were collected, and the vascular 
endothelial growth factor (VEGF) release was quantified 
using a VEGF ELISA kit (R&D Systems) according to 
manufacturer’s protocol. The data were represented as 
mean ± standard deviation (SD).
Evaluation of Bioactivity of Conditioned Media of 
Encapsulated hASC: Endothelial Cell Proliferation
For the cell proliferation assay, 1 ́  104 cells per well 
were seeded in 96-well plate in triplicate for each sam-
ple. After 24 h of culturing with DMEM with 2% FBS, 
the cells were washed twice with PBS. The conditioned 
media from the encapsulated and free cells under hypoxic/
normoxic conditions were added to the cells along with 
equal amount of fresh DMEM media supplemented with 
10% FBS. Wells treated with only DMEM with 10% FBS 
without any stimulation with conditioned media were 
taken as the control. The cells were grown at 37°C in 5% 
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CO
2
 for 4 days followed by MTS cell proliferation assay 
(Promega) according to manufacturer’s protocol.
Animal Model
Immunocompetent female Lewis rats (200–250 g, 
Charles River, QC) were used. All procedures were 
in compliance with the NIH and Canadian Council on 
Animal Care guidelines for the use and care of animals.
Intramyocardial Microcapsule Transplantation
The rats were maintained on standard rat chow diet. 
Myocardial infarction was induced by occlusion of 
the left anterior descending coronary artery (LAD) as 
described previously (2,5). Female Lewis rats were anes-
thetized using 5% isoflurane in an induction chamber. 
The rats were intubated with an 18-G catheter, ventilated 
at 80 breaths/min under anesthetic condition. A left tho-
racotomy was performed through the fourth intercostal 
space to expose the left ventricle. The left coronary artery 
was ligated 2 mm from its origin with a 7–0 polypropyl-
ene suture (Ethicon, Inc., Somerville, NJ). The ischemic 
myocardial segment rapidly became identifiable through 
its pallor and akinesia. Fifteen minutes after ligation of 
the artery, three 50-µl intramyocardial injections in the 
peri-infarct area of the left ventricle were given group-
wise according to Table 1 using a 27-gauge needle.
Retention of ASCs After 10 Weeks: Detecting the  
LacZ-Labeled Cells
Histological assessments of the left ventricular 
hearts were performed on rats after 10 weeks of myo-
cardial transplantation of LacZ-labeled hASCs. Hearts 
were stained for evidence of cell engraftment using 
b- galactosidase. For b-galactosidase activity, hearts 
were added to a solution containing 1 mg/ml 5-bromo-
4-chloro-3-indoyl-b-d-galactoside (X-gal), 2% dimethyl-











and 2 mM magnesium chloride, 0.02% Nonidet P40, and 
0.01% deoxycholate (5). The specimens were incubated 
in a 37°C incubator with a humidified atmosphere of 5% 
CO
2  
for 8 h. They were then washed with PBS and fixed 
in 2% paraformaldehyde overnight. After fixation, the 
myocardium was embedded in paraffin. Ribbon sections 
of tissue were cut on microtome and stained with eosin 
dye to detect cell cytoplasm.
Retention of ADSCs After 10 Weeks: Polymerase  
Chain Reaction Analysis
Random samples were selected from each group for 
polymerase chain reaction analysis to confirm the survival 
of the implanted male hASCs in the female rat hearts at week 
10. Genomic DNA was purified using DNeasy (Qiagen, 
Valencia, CA) according to the manufacturer’s instructions, 
and the presence of living human male cells in female rat 
hearts were confirmed by targeting a specific microsatel-
lite sequence within the human Y chromosome (DYS390). 
PCR was performed on equal amount of extracted DNA 
using Taq DNA Polymerase (Invitrogen). To detect 
specific gene product, the primer pair used was forward 
primer 5¢TATATTTTACACATTTTTGGGCC3¢ and re verse 
primer 5¢TGACAGTAAAATGAACACATTGC3¢ with an 
amplicon size of 250 bp (3,19). Amplifications were car-
ried out for 30 cycles at 94°C for 15 s (denaturation), 54°C 
for 20 s (annealing), and 72°C for 20 s (extension).
Myocardial Infarct Area Analysis
Ten weeks after myocardial infarction, rats were 
deeply anesthetized and sacrificed by rapid excision of 
the heart. The excised hearts were immediately soaked 
in cold saline to remove excess blood from the ventri-
cles and fixed in neutral-buffered 4% formalin. Paraffin-
embedded samples were sectioned at 5 µm, and Masson’s 
trichrome staining (DBS, Pleasanton, CA) was performed 
to delineate scar tissue (blue color) from the total area of 
myocardium (39). Masson’s trichrome-stained sections 
were captured as digital images and analyzed by ImageJ-
1.41 software. Infarct area, epicardial and endocardial 
length of infarction, and ventricular and septal wall thick-
ness were calculated and expressed as a percentage.
Immunohistochemistry for Detecting Neovascularization
Neovascularization was evaluated by analyzing the 
capillary and arteriole density in the peri-infarct area. 
For this, immunohistochemical staining was performed 
with antibodies against platelet endothelial cell adhe-
sion molecule (PECAM; Santa Cruz) for identification of 
Table 1. Animal Experimental Groups and Their Abbreviations
Groups (No. of Animals ) Samples Abbreviations
Group 1 (n = 4) Sham (control) S
Group 2 (n = 8) Empty microcapsules (control) M
Group 3 (n = 8) Free hASCs (1.5 ́  106) FC
Group 4 (n = 8) Microcapsulated hASCs
(1.5 ́  106)
MC
The cells used for myocardial transplantation were LacZ-labeled male human adipose stem cells (hASCs).
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endothelial cells and smooth muscle a-actin (Santa Cruz) 
for tracing the smooth muscle cells. Briefly, for measure-
ment of capillary density, five fields in the peri-infarct 
area were imaged with 200´ magnification and average 
numbers of capillaries with less than 10 µm diameter 
were counted. The capillary density was quantified as the 
(mean total PECAM-positive microvessels)/mm2 using 
three tissue sections spanning per-infarct tissue region of 
each animal. Similarly, arteriole densities were quanti-
fied as the (mean total smooth muscle a-actin-positive 
microvessels)/mm2.
Echocardiography and Cardiac Performance
Transthoracic echocardiography was performed on 
all surviving animals in the four groups before operation 
(baseline) and before sacrifice on week 10. Echocardio-
grams were obtained with a commercially available sys-
tem (SonoSite, Titan-Washington, Seattle, WA) equipped 
with a 15-MHz transducer, according to the American 
Society of Echocardiology leading-edge method (5). 
After sedating the animals, left ventricular end-diastolic 
(LVEDD) and end-systolic (LVESD) diameters were mea-
sured with M-mode tracings between the anterior and pos-
terior walls from the short-axis view just below the level 
of the papillary muscles of the mitral valve. Two images 
were obtained in each view and averaged over three con-
secutive cardiac cycles. Fractional shortening (FS) was 
determined as [(LVEDD - LVESD) / LVEDD] ́  100 (%). 
All measurements were performed by one experienced 
observer who was blinded to the treatment groups.
Statistical Analysis
All data are expressed as mean ± standard deviation 
(SD). Multiple group comparison was performed by one-
way analysis of variance (ANOVA) followed by post 
hoc analysis using the Bonferroni procedure for multiple 
comparison of means. Values of p < 0.05 were considered 
to be statistically significant.
RESULTS
Characteristics of the GCAC Microcapsules 
Encapsulating hASCs
The reaction between chitosan and genipin occurred 
moderately after mixing the two solutions and could 
be monitored by detecting the changes in the physical 
appearance of the mixture from time to time. Results 
in Figure 2 exemplifies that the chitosan-genipin reac-
tion generated a fluorescent bright circle circumscribing 
each microsphere core after 12 h of exposure of the AC 
capsule to genipin, which was not detected in the one 
that was not exposed to genipin. This is in accordance 
to our earlier results (7,8). Figure 2 (bottom) shows the 
fluorescence profile corresponding to the line across the 
optical section of the microcapsules. It was clear that 
the intensity of the inner alginate cores was similar to 
that of the background signals, whereas peaks corre-
sponding to the fluorescence of the microcapsule mem-
brane appeared with the relatively higher intensity at the 
capsular surface. The cells were also viable in both AC 
and GCAC capsules, as detected by calcein staining. 
Bright field picture of the cell containing microcapsules 
show that they were generally spherical and uniform 
in shape and size, with an average diameter of about 
200 µm. Figure 3 shows that the mesh-like porous inter-
nal morphology of blank microcapsule (Fig. 3A, B). 
The morphology of the cell-loaded microcapsules was 
also similar (Fig. 3C) to the empty one, confirming that 
the internal structure of the microcapsules was not influ-
enced by the hASC loading.
Viability of the hASCs was also assessed at regular 
intervals using polyanionic calcein AM and ethidium 
homopolymer EthD-III dyes. Figure 4 is a representa-
tive example of the encapsulated cells showing calcein-
stained encapsulated viable cells and EthD-III-stained 
dead cells on day 21. The fluorescent outer circles of 
GCAC microcapsules, due to genipin-chitosan cross-
linking, also dis appeared after day 21. This indicates 
that the outer surface has gradually started disintegrat-
ing, although the exact time of degradation was not ana-
lyzed in this study.
Efficient Release of hVEGF Molecules From 
Encapsulated hASCs Under Hypoxic Conditions
In order to understand the therapeutic potential of 
encapsulated cells in infarcted heart, we checked the 
VEGF release potential of the encapsulated cells under 
hypoxic condition, which is a very prevalent condition in 
an ischemic myocardial environment. The data in Figure 5 
show that, under hypoxic condition, the encapsulated 
cells secretes significantly increased amount of VEGF 
at 24 h (6.02 ng/4 ́  106 cells vs. 3.85 ng/4 ́  106 cells; 
p < 0.05), 48 h (16.21 ng/4 ́  106 cells vs. 4.63 ng/4 ́  106 
cells; p < 0.05), and 96 h (20.58 ng/4 ́  106 cells vs. 
6.1 ng/4 ́  106 cells; p < 0.05) in comparison to that under 
normoxic conditions.
hVEGF Released From Encapsulated hASCs Have 
Mitotic Effect on Endothelial Cells
To check the biological activity of the released pro-
tein, a HUVEC proliferation assay was performed on 
the released conditioned media from 96 h hypoxic and 
normoxic hASC encapsulated samples. The samples 
with high VEGF concentrations, that is, from hypoxic 
conditioned media from free and encapsulated cells, sig-
nificantly increased the proliferation rate of HUVECs 
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in comparison to that from normoxic conditioned media 
(163% in hypoxic free and 154.5% in hypoxic encapsu-
lated cells against 31% proliferation in control; 100% 
proliferation was taken as baseline for normoxic free 
cells) as illustrated in Figure 6. Under hypoxic condition, 
conditioned media from both encapsulated and nonen-
capsulated cells induced around fivefold cell prolifera-
tion compared to the unstimulated control, while under 
normoxic condition the proliferation was around 3.3-fold 
in both cases. Thus, the extent of cell proliferation was 
directly proportional to the released VEGF amount by the 
hASCs under different conditions.
Higher Retention and Survival Rate of Transplanted 
Cells Using GCAC Microcapsules
To analyze whether the microcapsules were able to 
protect the cells against the harsh external beating envi-
ronment in the heart, harvested heart tissue samples were 
stained with X-gal in order to trace the transplanted LacZ 
gene containing cells in the heart. The picture in Figure 7A 
Figure 2. Confirmation of reaction between chitosan layer and outer genipin coating in preparing genipin-cross-linked alginate chito-
san (GCAC) microcapsules using confocal microscope. The above figure represents the confocal laser scanning microscopic images of 
the AC (A–C) and GCAC microcapsules (D–F) at an excitation of 488 nm and emission of 530 nm. The microcapsular AC membrane 
was cross-linked with genipin (5.0 mg/ml) at 37°C for 12 h. The bright fluorescence on the outer surface of the GCAC capsules indi-
cates the complete cross-linking between genipin and chitosan. This fluorescence was not there in AC capsules that were no treated 
with genipin. The encapsulated viable cells, stained by calcein AM, are shown as the dots inside the capsule. Scale bar: 50 µm. (G) 
Fluorescence intensity profile corresponding to the white dotted x-axis line drawn across the plane of the GCAC microcapsules using 
ImageJ-1.43 m.
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gives us a qualitative idea of the amount of encapsu-
lated cells survived in the heart in comparison to free 
ones. Although the retention of cells were higher in the 
encapsulated group, there was no trace of the polymeric 
capsules after 10 weeks, which probably got degraded 
and bioresorped in the body over time leaving the cells 
behind. The infarct and peri-infarct portions of the heart 
tissues were also used for DNA extraction. This was 
used to detect the presence of Y chromosome of trans-
planted hASC in the female rat heart using standard PCR. 
Equal amounts of tissue samples from the peri-infarct 
region of heart were taken for DNA extraction. The gel 
electrophoresis of the PCR products shows a clear dis-
tinction in band intensities of encapsulated and free cells 
(Fig. 7B). The encapsulated cells showed 3.54 times 
more retention of viable transplanted cells in the heart in 
comparison to nonencapsulated cells (100% vs. 28.2%; 
p < 0.05) as quantified by relative band intensities using 
ImageJ software. This semiquantitative analysis sug-
gests that, using microencapsulation technology, we 
need less cell number to achieve desirable cell retention 
at the target site.
Figure 3. Scanning electron microscope images of microcapsules with and without hASCs. Images of internal morphology of cell 
loaded with genipin-cross-linked alginate chitosan (GCAC) microcapsules (A; scale bar: 100 µm; original magnification: 500´) with 
subset showing a higher magnification (1,300´) of the capsular outer membrane (scale bar: 40 µm). The microphotograph at the bot-
tom represents the internal mesh-like scaffold structure of the empty GCAC microcapsule (B; scale bar: 50 µm; original magnification: 
800´) and hASC loaded GCAC microcapsule (C; scale bar: 50 µm; original magnification: 800´) with the subset showing the magni-
fied image of the entrapped cell within the capsular scaffold (scale bar: 10 µm; original magnification: 3,013´).
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Microencapsulated hASCs Efficiently Reduce Fibrosis  
in the Infarcted Tissue
Macroscopic views of Masson’s trichrome-stained 
hearts are shown in Figure 8. In all the groups, stained 
fibrous infarct areas were clearly observed as gray 
areas in the heart sections 10 weeks after myocardial 
infarction. We measured the infarct size and other 
parameters in the left ventricles at the section of the 
middle point between ligation and apex as previously 
described elsewhere (39). As shown in Table 2, the 
average percentage infarction size in hearts of MC 
group (21.6% ± 1.1%) was significantly reduced com-
pared to that in control hearts (33.3% ± 3.2% in M and 
27.2% ± 3.1% in FC). Thin left ventricular wall with 
dilated left ventricular cavities (average thickness: 
0.86 mm and 1.41 mm) were observed in the M and FC 
control groups, while the hearts in the MC group had 
lesser infarcts and thicker left ventricular wall (aver-
age thickness: 1.85 mm) than the control hearts. There 
were also significant differences between the control 
groups and the FC group with respect to the percent-
age endocardial infarction length and the percentage 
epicardial infarction length.
Induction of Myocardial Angiogenesis and 
Arteriogenesis
In this section, we tried to comprehend whether it was 
the higher angiogenic effect of the microencapsulated 
Figure 4. Viability of microencapsulated stem cells after 21 days of culture in DMEM supplemented with 10% FBS at 37°C. Viability 
tests were done by using the calcein AM and ethidium homopolymer dye. Representative bright field and fluorescent images of a cap-
sule encapsulating the cells under 400´ magnifications in a fluorescence microscope. Scale bar: 50 µm.
Figure 5. Modulation of vascular endothelial growth factor (VEGF) secretion by microencapsulated 
adipose stem cells under hypoxic and normoxic condition. Secretion of VEGF by GCAC encapsu-
lated hASCs cultured in normoxic or hypoxic conditions over 24, 48, and 96 was measured by ELISA 
and is presented as mean ± SD nanogram of secreted factor normalized to 4 ́  106 cells at time of 
harvest. VEGF production in normoxia and hypoxia was compared with one-way ANOVA analysis 
(n = 3; *p < 0.05).
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hASCs that was responsible for the scar area reduc-
tion in treatment groups. We assessed the neovascu-
lature formation in the peri-infarct area by detecting 
the capillary (Fig. 9A–D) and artery densities (Fig. 
9E–H). As shown in Figure 9I, we noticed a signifi-
cant improvement in angiogenesis in the FC and MC 
groups compared to the M (197 ± 24.1/mm2 for MC, 
144.4 ± 15.45/mm2 for FC vs. 67.33±17.7/mm2 for 
control, p < 0.01). Moreover, MC
 
group also showed 
significantly higher capillary density compared to FC. 
Similar results were obtained with arteriole density in 
MC group (20.6 ± 4.9/mm2 for MC, 17.5 ± 3.92/mm2 
for FC
 
vs. 6.9 ± 2.01/mm2 for control, p < 0.001) as 
presented in Figure 9J. Unlike capillary density, MC 
group showed no significant enhancement in arteriole 
density compared to FC.
Attenuation of the Progression of Cardiac Dysfunction 
by Microencapsulated hASCs
Here we assessed the cardiac function 10 weeks 
after myocardial infarction in the all the four groups by 
echocardiography. The cardiac functional parameters 
evaluated by M-mode echocardiography, 10 weeks after 
LAD ligation, are shown in Figure 10. In the control 
group (M), significantly decreased fractional shortening 
was seen, a typical indication of postinfarction cardiac 
failure. In the group that underwent microencapsulated 
cell transplantation (MC), significantly higher FS was 
observed as compared to groups M (group MC: 24.2% ± 
2.1%; group FC: 19.1% ± 0.5%; group M: 12.0% ± 4.0%; 
p < 0.05). FS data indicate a significant cardiac function 
improvement in group MC compared to group FC. Thus, 
the analysis using echocardiographic FS% data suggests 
that encapsulated hASCs can be a better alternative to 
free hASCs to improve cardiac function after acute myo-
cardial damage.
DISCUSSION
Cardiomyocytes are considered to be terminally dif-
ferentiated cells, and regeneration is limited in adult 
life (48). Thus, the irreversible damage of infarction in 
the heart increases the risks of having severe compli-
cations such as myocardial wall rupture, arrhythmia, 
aneurysms, and eventual heart failure (20). Application 
of mesenchymal stem cell therapy in such cases have 
become one of the most ardently researched and debated 
subjects in the last 10 years (13,16,17,46). The essence 
of mesenchymal stem cells can be explained through 
three essential characteristics: firstly their multilineage 
differential potential, secondly their immunomodula-
tory effect, and thirdly their ability to self-regenerate 
for an unlimited amount of time (4). In this study, we 
have used xenogeneic donor mesenchymal stem cells 
from adipose origin in immunocompetent rats as an 
alternative to widely used mesenchymal bone marrow 
stem cells.
Figure 6. Evaluation of bioactivity of released vascular endothelial growth factor (VEGF) from 
adipose stem cells: endothelial cell proliferation assay. Effects of free and encapsulated hASC super-
natants on human umbilical vein endothelial cell (HUVEC) proliferation are represented as percent-
age of cells on day 4 under hypoxic and normoxic conditions (mean ± SD). For this unstimulated 
endothelial cells are taken as the control. The average cell number in wells treated with normoxic 
media from free cells on day 4 of proliferation was taken as 100%, and cells from other wells were 
normalized to it. Numbers of endothelial cells exposed to normoxic media only are significantly lower 
than those exposed to hypoxic media. This was same for both free and encapsulated cells. VEGF pro-
duction in normoxia and hypoxia was compared with one-way ANOVA analysis (n = 3; *p < 0.05).
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Apart from direct free cell delivery, micro- and nano-
scaffold mediated delivery of stem cells is another widely 
used approach that has been exploited in the field of regen-
erative medicine (31). Seeding cells on these scaffold-
ing systems are used to provide a suitable environment 
for cell colonization, proliferation, and differentiation. 
Recently, Wei et al. reported the development of a bioen-
gineered cardiac patch composed of a sliced porous bio-
logical scaffold inserted with multilayered mesenchymal 
stem cells for myocardial regeneration (43). An array of 
biomaterials have been used to create scaffolds includ-
ing type I collagen, a biocompatible polymer onto which 
Figure 7. Higher retention of adipose stem cells (hASCs) in the left ventricular myocardium using microcapsules 10 weeks post 
transplantation. Histological sections of the left ventricular heart stained with X-gal in (Ai) encapsulated hASCs group and (Aii) free 
hASCs group. The transplanted hASCs are indicated by the arrows. (Ai’) X-gal stained microencapsulated hASCs, with stable LacZ 
expression, which were used for transplantation in microencapsulated hASC group. This positive X-gal staining illustrates that the 
encapsulated cells were viable and express the LacZ transgene from within the microcapsules. (Aii’) X-gal stained monolayer hASC 
culture, stably transduced with LacZ gene, which were used for transplantation in free hASC group. Scale bars: 100 µm. (B) PCR prod-
ucts (250 bp) specific for the human Y chromosome (DYS390 sequence) as detected in 2% agarose gel. There were clear and distinct 
bands in all the female rat hearts with microencapsulated male hASCs at 10 weeks (MC). These band intensities were much lower in 
free hASC groups (FC). Two PCR products from each group are shown here. The ImageJ analysis of the band intensities show the FC 
group with average 28% band intensity taking the band intensity of MC group as 100%. C represents the positive control for the in vitro 
cultured male hASCs, whereas M represents the negative control for the group M treated with empty microcapsules and S represents 
the myocardium for the sham group S. †Statistically significant between microencapsulated hASCs and free hASCs.
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the cells have a high affinity and poly lactide-co-glycolic 
acid, a biodegradable polymer supporting cell stability 
(18,22,44,45). In an interesting study, Zhang et al. 
reported that microencapsulated xenogeneic Chinese 
hamster ovary cells genetically modified to express 
VEGF can induce significant therapeutic effects in isch-
emic heart disease (51). In a similar approach, Goren et 
al. also reported microencapsulated mesenchymal stem 
cells are ideal candidates for hypoimmunogenic long-
term cell-based therapy (12). Although microcapsules 
prepared from alginate and poly-l-lysine polymers are 
being used extensively for such long time study for 
their ability to support cell viability, several studies 
have demonstrated that they lack mechanical strength 
and stability when applied over the long term in vivo, 
leading to leakage of the encapsulated cells (25,26,34). 
Furthermore, the addition of PLL to alginate stimulates 
necrosis of the encapsulated cells (14,15). As most syn-
thetic polyelectrolyte materials exhibit a moderate level 
of cell cytotoxicity, naturally occurring materials consti-
tute ideal polymers for live cell encapsulation. In recent 
years, genipin has drawn considerable research interests 
as an alternative cross-linker due to its natural origin 
and low cytotoxicity, allowing for mild but effective 
chemical cross-linking. Our earlier studies have shown 
successful encapsulation of liver cells within genipin 
cross-linked microcapsules for therapeutic applications 
(7). Preliminary studies (data not shown) show that the 
empty microcapsules can be intact for at least 10 weeks 
in the culture media. But once they are entrapping the 
Figure 8. Effect of microencapsulated and free human adipose stem cells (hASCs) on infarcted rat heart: scar area detection. Ten 
weeks after myocardial infarction, the heart was excised and stained using Masson’s trichrome staining method where the gray-stained 
area represents the scar tissues (I: infarcted area in left ventricular wall; II: noninfarcted left ventricular portion; III: septum). Infarct 
scar area and the total area of LV myocardium measured automatically by the means of ImageJ-1.41 (NIH) software, as shown in 
subset of Group MC. Gray area represents extracellular matrix (ECM) deposition in scar tissue and bright area represents myocardium. 
Compared to groups with microcapsules and free hASCs, encapsulated hASC group had less extracellular matrix deposition area. 
Scale bars: 2 mm.
Table 2. Effect of Microencapsulated Male Human Adipose-Derived Stem Cells (hASCs) on Infarcted Heart: Morphometric Analysis 



















S (n = 4) No infarction 2.9 ± 0.4* No infarction No infarction 3.7 ± 0.08*
M (n = 8) 33.3 ± 3.2 0.86 ± 0.17 47.4 ± 1.05 61.5 ± 4.32 4.3 ± 0.05
FC (n = 8) 27.2 ± 3.1* 1.41 ± 0.1* 38.2 ± 3.88* 53.1 ± 2.02* 4.05 ± 0.2*
MC (n = 8) 21.6 ± 1.1*† 1.85 ± 1.3*† 32.2 ± 2.42*† 44.7 ± 4.12*† 3.98 ± 1.1*
Values indicate the mean ± SD (n = 8; n = 4 for sham). Rats were sacrificed 10 weeks after myocardial infarction. All parameters were measured on 
the midline horizontal sections between ligation point and apex of heart and calculated according to the following formulae: % infarct size = infarct 
area / total LV area ́  100; % endocardial infarct length = endocardial length of infarction/endocardial circumference of LV ́  100; % epicardial infarct 
length = epicardial length of infarction/epicardial circumference of LV ́  100.
* Statistically significant compared to control (microcapsules only).
† Statistically significant between microencapsulated hASCs and free hASCs. 
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cells, the microcapsules tend to start degrading after 
3–4 weeks (Fig. 4). This is because of the proliferation 
of encapsulated cells under in vitro culture conditions, 
which is not the case under harsh in vivo external envi-
ronment. But the in vivo data (Fig. 7) confirm that the 
polymeric microcapsule completely disappeared after 10 
weeks, leaving the entrapped cells in viable condition. 
This confirms the bioresorbable and nontoxic nature of 
the degraded products of the polymeric microcapsule. 
And this transient nature of the micro capsule is desir-
able; it disappears from the organ once its job is done. 
In the present study, our results confirm the higher reten-
tion potential of microencapsulated hASCs in vivo as 
shown in Figure 7 and establish the superior features of 
biocompatible cell containing GCAC microcapsules in 
improving heart function in an extreme model of xeno-
geneic mismatch (Table 1 and Fig. 10). An important 
point while injecting the microcapsules is the needle 
size, which should not be too small that it breaks the 
capsules while injecting, at the same time it should not 
be too big for intramyocardial injection procedure. As it 
is very difficult to directly quantify the number of trans-
planted cells in the heart after 10 weeks, we relied on the 
relative comparison between the experimental groups. 
Although the number of transplanted cells used here was 
optimal to treat the rat heart infarction, this number will 
vary based on the animal models used in the respective 
studies. By attenuating the contractile dysfunction and 
Figure 9. Angiogenesis and arteriogenesis in the peri-infarct area. Immunohistological staining of platelet endothelial cell adhe-
sion molecule (PECAM) to detect endothelial cells in (A) Sham, (B) M, (C) FC, and (D) MC groups. Immunohistological staining 
of smooth muscle a-actin for smooth muscle cells in (E) S, (F) M, (G) FC, and (H) MC groups. Scale bar: 50 µm. Quantification of 
(I) capillary and (J) arteriole density. Data are expressed as mean density ± SD. One-way ANOVA analysis: *statistically significant 
compared to control (M), †statistical significance between microencapsulated hASCs and free hASCs. 
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pathological remodeling, the microencapsulated hASCs 
contributed significantly and better than free hASCs to 
a remarkable recovery in ventricular performance after 
myocardial infarction.
This is the first study to our knowledge, where hASCs 
are being successfully encapsulated in polymeric micro-
capsules and delivered as xenotransplant in immuno-
competent rats with acute myocardial infarction. This is 
also the first time where the GCAC microcapsules have 
been tested in vivo. The results support our hypothesis 
that the ASCs, encapsulated in GCAC microcapsules, 
survive longer and sustain their functional properties in 
the beating heart compared to free cells, which, in turn, 
induce reduction of the infarcted scar area and improve 
cardiac function significantly. Although the encapsu-
lated microcapsules significantly reduced the myocar-
dial infarction in comparison to free cells and untreated 
groups, the underlying mechanism is not fully under-
stood. It is true that we were able to achieve our goal 
for better retention of the transplanted viable cells in 
the infarct area, but we do not know how the encapsu-
lated cells induce its therapeutic effect in vivo. Previous 
studies have reported the transdifferentiation of ASCs 
to cardiomyocytes in the cardiovascular environment, 
while others attribute the improvement in cardiac func-
tion to the paracrine activity of stem cells or cell fusion 
(35,36,42). The in vivo studies of microencapsulated 
hASCs presented here suggest that vasculogenesis 
(Fig. 9) can be a probable mechanism of therapeutic 
action. The in vitro data confirm that microencapsu-
lated cells can effectively induce angiogenesis under 
hypoxic condition by overexpression of VEGF. VEGF 
protects the blood vessels from apoptosis, modulates 
vasomotor response, and supports vessel formation in 
the ischemic area, thus reducing the infarct size in vivo 
by improving blood flow (32,52). The results from the 
present study suggest that the improved heart function 
is a combinatorial effect of at least two major compo-
nents—the survival of a significantly higher number 
of grafted cells even after 10 weeks post transplanta-
tion and related angiogenic effects of the implanted 
cells. In terms of future concern, an elaborate in vivo 
work is needed to be done to evaluate whether the 
genipin cross-linked polymeric microcapsules have 
Figure 10. Functional effects of microencapsulated and free human adipose stem cells (hASCs) on infarcted rat heart: evaluation of 
cardiac function by echocardiographic analysis. Ten weeks after myocardial infarction, echocardiography was performed to evaluate 
cardiac function. (A) M-mode echocardiograms from different groups of rats. Effects of microencapsulated hASCs on left ventricular 
(LV) fractional shortening on week 10 are also presented (B). Values indicate the mean ± SD (n = 8; n = 4 for sham). (B) Left ventricular 
fractional shortening also improved significantly in group MC compared to group M and group FC. *Statistically significant compared 
to control (microcapsules only). †Statistically significant between microencapsulated hASCs and free hASCs. 
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any significant effect on the host immune system and 
on myocardial and serum cytokine profile. Studies are 
also needed to be done to accurately determine the 
degradation rate of the GCAC capsules in the in vivo 
environment. Application of cell-based gene therapy 
using GCAC microencapsulated genetically modified 
hASCs to modulate inflammatory effects or promote 
angiogenesis can be the next step for myocardial treat-
ment (6,38,39,52). Another interesting field of research 
will be to further enhance the biocompatibility of the 
GCAC microcapsules by using cyclic arginine-glycine-
aspartate (RGD)-conjugated alginate polymers instead 
of normal alginate, which has shown to help recover 
cardiac function in infarcted heart (50). To conclude, 
the present study demonstrates the first successful step 
to introduce ASCs for improved xenogeneic myocar-
dial transplantation using novel biocompatible and 
biodegradable microcapsules. Further interdiscipli nary 
research on developing improved cell-entrapped poly-
meric microcapsules armed with targeting molecules 
for site-specific delivery will help us bring this technol-
ogy much closer to clinical applications.
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